ATE221083T1 - Glialmitogene faktoren, ihre herstellung und verwendung - Google Patents

Glialmitogene faktoren, ihre herstellung und verwendung

Info

Publication number
ATE221083T1
ATE221083T1 AT92907539T AT92907539T ATE221083T1 AT E221083 T1 ATE221083 T1 AT E221083T1 AT 92907539 T AT92907539 T AT 92907539T AT 92907539 T AT92907539 T AT 92907539T AT E221083 T1 ATE221083 T1 AT E221083T1
Authority
AT
Austria
Prior art keywords
factors
glialmitogenic
production
factor
new
Prior art date
Application number
AT92907539T
Other languages
English (en)
Inventor
Andrew David John Goodearl
Michael Derek Waterfield
Paul Stroobant
Luisa Minghetti
Mark Andrew Marchionni
Original Assignee
Ludwig Inst Cancer Res
Cambridge Neuroscience Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cambridge Neuroscience Res Inc filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE221083T1 publication Critical patent/ATE221083T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92907539T 1991-04-10 1992-04-03 Glialmitogene faktoren, ihre herstellung und verwendung ATE221083T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919107566A GB9107566D0 (en) 1991-04-10 1991-04-10 Glial mitogenic factors,their preparation and use
PCT/GB1992/000595 WO1992018627A1 (en) 1991-04-10 1992-04-03 Glial mitogenic factors, their preparation and use

Publications (1)

Publication Number Publication Date
ATE221083T1 true ATE221083T1 (de) 2002-08-15

Family

ID=10692987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907539T ATE221083T1 (de) 1991-04-10 1992-04-03 Glialmitogene faktoren, ihre herstellung und verwendung

Country Status (13)

Country Link
EP (1) EP0579640B1 (de)
JP (1) JPH06507544A (de)
KR (1) KR100274305B1 (de)
AT (1) ATE221083T1 (de)
AU (2) AU1450992A (de)
CA (1) CA2108119C (de)
DE (1) DE69232693T2 (de)
DK (1) DK0579640T3 (de)
GB (1) GB9107566D0 (de)
IE (1) IE921062A1 (de)
PT (1) PT100344B (de)
WO (1) WO1992018627A1 (de)
ZA (1) ZA922441B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
EP0656069A4 (de) * 1992-08-10 1996-07-10 Cambridge Neuroscience Inc Inhibitoren der zellproliferation, ihre herstellung und nutzung.
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
DE69732711T2 (de) 1996-07-12 2006-03-16 Genentech, Inc., South San Francisco Gamma-heregulin
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
WO1999031505A1 (en) * 1997-12-15 1999-06-24 Shire Laboratories Inc. Neurotrophic factor assay
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7241392B2 (en) 2004-09-09 2007-07-10 Dresser-Rand Company Rotary separator and method
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) 2005-12-30 2015-03-03 Zensun Shanghai Science And Technology Ltd Liberación extendida de neurregulina para mejorar la función cardíaca
EP3777878A1 (de) 2008-08-15 2021-02-17 Acorda Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung während nicht akuter zeiträume nach neurologischen verletzungen des zns
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP3895724B1 (de) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Verlängerte freisetzung von neuregulin zur behandlung von herzinsuffizienz

Also Published As

Publication number Publication date
EP0579640B1 (de) 2002-07-24
PT100344A (pt) 1993-07-30
DK0579640T3 (da) 2002-11-11
IE921062A1 (en) 1992-10-21
GB9107566D0 (en) 1991-05-29
DE69232693T2 (de) 2003-04-03
PT100344B (pt) 1999-08-31
JPH06507544A (ja) 1994-09-01
CA2108119A1 (en) 1992-10-11
AU6808396A (en) 1997-01-16
WO1992018627A1 (en) 1992-10-29
AU703772B2 (en) 1999-04-01
EP0579640A1 (de) 1994-01-26
AU1450992A (en) 1992-11-17
CA2108119C (en) 2009-06-30
KR100274305B1 (ko) 2000-12-15
DE69232693D1 (de) 2002-08-29
ZA922441B (en) 1992-11-25

Similar Documents

Publication Publication Date Title
ATE221083T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE139261T1 (de) Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
DE69215434D1 (de) 1,3,5-Triazinderivate, ihre Herstellung und ihre Verwendung als Lichtschutzmittel
EP1138673A3 (de) Neue Carbamat- und Harnstoffderivate als Mittel gegen Multidrugresistenz
DE3885534D1 (de) Arylphosphorderivate, ihre Herstellung und Verwendung.
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE68906011D1 (de) Chitosan enthaltendes kosmetisches praeparat.
NZ225770A (en) Compositions of substituted 1,2,3-triazoles
DE69204290D1 (de) Verwendung von 1,2,2,3,3-pentafluorpropan.
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
DE58908788D1 (de) Modifizierte Blockpolymerisate, ihre Herstellung und Verwendung.
DE59606806D1 (de) Polymerholz-formkörper, ihre herstellung und verwendung
ATE39694T1 (de) (pyrrol-1-yl)-phenyl-dihydropyridazinone, ihre herstellung und verwendung.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE68908389D1 (de) Amidofluoroverbindungen, ihre herstellung und ihre verwendung.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.
DE59203456D1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung.
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.
ATE132500T1 (de) 24r-scymnol, herstellung und verwendung
DE69212484D1 (de) Herstellung von 1,1,1-trifluoro-2-chloroethan und/oder 1,1,1,2-tetrafluoroethan
ATE128867T1 (de) Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma.
DE69116057D1 (de) Mikrobische Herstellung des 13-beta-13-deoxy-22,23,-dihydroavermectin-Bla/B1b-Aglycons
DE3878988D1 (de) 1,2-di(4-isobutylphenyl)aethylen, dessen herstellung und verwendung als zwischenprodukt.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0579640

Country of ref document: EP